Tirzepatide versus semaglutide for weight loss in patients with type 2 diabetes mellitus: A value for money analysis
Authors' conclusion
Tirzepatide provides better value for money than semaglutide for weight reduction.
Study context
- Population
- Patients with T2D (weight reduction data from published trial results)
- Comparison
- High-dose tirzepatide vs semaglutide
- Outcome
- Cost needed to treat to achieve a 1% reduction in body weight
Methodological detailsvalue for money analysis, cost needed to treat, scenario analysis, data from SURMOUNT-1 and STEP 1 trials, US GoodRx prices as of October 2022
- Value for money analysis
- Cost needed to treat
- Scenario analysis
- Data from SURMOUNT-1 and STEP 1 trials
- US GoodRx prices as of October 2022
Main finding
As reported in the abstract
Cost needed to treat per 1% body weight reduction
Tirzepatide
$985
95% CI $908-$1075
Semaglutide
$1845
95% CI $1707-$1989
Further findings
| Outcome | Tirzepatide | Semaglutide |
|---|---|---|
| Weight loss | 17.8% (95% CI 16.3%–19.3%) | 12.4% (95% CI 11.5%–13.4%) |
| Total drug cost · 72 weeks (tirzepatide); 68 weeks (semaglutide) | $17 527 | $22 878 |
Original publication
Tirzepatide versus semaglutide for weight loss in patients with type 2 diabetes mellitus: A value for money analysis. Diabetes Obes Metab. Published 27 December 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →